Utility and outcomes of fine-needle aspiration biopsy in Hodgkin's disease

Authors

  • Wendy S. Moreland M.D.,

    1. Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    Search for more papers by this author
  • Kim R. Geisinger M.D.

    Corresponding author
    1. Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • Department of Pathology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157
    Search for more papers by this author

Abstract

We present our 10-year experience, including clinical utilization and outcomes, with fine-needle aspiration biopsy (FNAB) in Hodgkin's disease (HD). Eighty-six cases from 68 patients with HD that were evaluated by FNAB were identified over a 10-year period. Medical records of these 68 patients were reviewed. Thirty-seven patients with primary HD underwent 41 aspirates. A diagnosis of HD was yielded in 12 and suggested in 13 cases (sensitivity 86.2%, false-positive 0%). Nine were diagnosed as atypical lymphoid cells, four as hyperplasia/other, and three as unsatisfactory. With these diagnoses, six patients began treatment without tissue exam. Thirty-five patients with suspected recurrent HD underwent 45 FNABs. Recurrent HD was confirmed in 15 and suggested in 12 aspirates (sensitivity 81.3%, false-suspicious 14.3%). With these diagnoses, 22 patients began treatment for recurrence without tissue exam. FNAB is useful both for establishing a primary diagnosis and confirming recurrence in HD and thus has a high utilization at our institution. In many instances, patients can begin therapy, negating the need for formal tissue exam. Diagn. Cytopathol. 2002;26:278–282. © 2002 Wiley-Liss, Inc.

Ancillary